{"url":"https://nivawealth.com/firms/avoro-capital-advisors-154091","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/154091","regulatoryAum":13550212784,"crd":"154091","secFileNumber":"801-74391","legalName":"Avoro Capital Advisors LLC","displayName":"Avoro Capital Advisors","website":"HTTP://www.avorocapital.com","founded":null,"organization":"Delaware limited liability company","fiscalYearEnd":"December","headquarters":{"street":"110 Greene Street, Suite 800","city":"New York","state":"NY","stateName":"New York","country":"United States","postalCode":"10012"},"tradeNames":[],"registration":{"secApproved":"30 March 2012","noticeFilings":null,"latestNoticeFiling":null},"staff":{"employees":19,"advisory":11,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"discretionary":13550212784,"discretionaryAccounts":3,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":33,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":3,"regulatoryAum":13550212784}],"fees":[],"feeNotes":[],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Avoro Capital Advisors has custody of $13.55B for 3 clients.","otherCustodians":[],"leadership":[{"name":"Neil Cammarosano","title":"Chief Financial Officer","crd":"6129331"},{"name":"Scott Epstein","title":"Chief Operating Officer and Chief Compliance Officer","crd":"2440142"},{"name":"Behzad Aghazadeh","title":"Managing Director","crd":"5195130"}],"ownership":[{"label":"Avoro Capital L.P.","detail":"Direct owner in the 75% or more ownership band and a control person, since May 2019."},{"label":"Behzad Aghazadeh","detail":"Indirect owner: a limited partner of Avoro Capital L.P. in the 50% to 75% band and a control person, since May 2019. Also a member of Avoro Capital GP LLC in the 50% to 75% band and a control person, since May 2019.","parent":"Avoro Capital L.P."},{"label":"Avoro Capital GP LLC","detail":"Indirect owner: general partner of Avoro Capital L.P. and a control person, since May 2019.","parent":"Avoro Capital L.P."},{"label":"Garheng Kong","detail":"Indirect owner: a member of Avoro Capital GP LLC in the 50% to 75% band, since May 2019.","parent":"Avoro Capital GP LLC"}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":0,"privateResidences":0},"listedOfficeAddresses":1,"officesByState":[{"state":"New York","offices":1,"addresses":[{"street":"110 Greene Street, Suite 800","city":"New York","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"212-937-4970","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":2},"sources":{"adv1FilingDate":"5 March 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/154091/PDF/154091.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Avoro Capital Advisors have?","answer":"Avoro Capital Advisors has 3 clients and manages $13.6 billion for them, as of March 2026.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 5 March 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Avoro Capital Advisors offer?","answer":"Avoro Capital Advisors provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Avoro Capital Advisors have?","answer":"Avoro Capital Advisors has 0 investment adviser representatives registered with state securities authorities, out of 19 employees, and 11 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Avoro Capital Advisors?","answer":"Avoro Capital Advisors is owned through a chain of holding companies by Behzad Aghazadeh and Garheng Kong. Its direct owner is Avoro Capital L.P. (75% or more).","source":"Form ADV Part 1A, Schedules A and B, filed 5 March 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Avoro Capital Advisors get paid?","answer":"Avoro Capital Advisors is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}}],"holdings":{"url":"https://nivawealth.com/firms/avoro-capital-advisors-154091/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1633313/000110465926096427/0001104659-26-096427-index.html","totalValue":11136250185,"positionCount":26,"top10Share":0.7945915410484288,"top10":[{"issuer":"UNITED THERAPEUTICS CORP","titleOfClass":"Common","cusip":"91307C102","value":1505082912,"shares":2777777,"shareType":"SH","priorValue":1559537400,"priorShares":2630000},{"issuer":"ASCENDIS PHARMA","titleOfClass":"ORDINARY SHARES","cusip":"K08588103","value":1363235526,"shares":5111111,"shareType":"SH"},{"issuer":"KRYSTAL BIOTECH INC","titleOfClass":"Common","cusip":"501147102","value":1073713003,"shares":2888888,"shareType":"SH","priorValue":746257548,"priorShares":2888888},{"issuer":"MADRIGAL PHARMACEUTICALS INC","titleOfClass":"Common","cusip":"558868105","value":984408154,"shares":1833333,"shareType":"SH","priorValue":951763208,"priorShares":1818181},{"issuer":"ARGENX SE","titleOfClass":"Sponsored ADR","cusip":"04016X101","value":927770000,"shares":1000000,"shareType":"SH","priorValue":730250000,"priorShares":1000000},{"issuer":"ARROWHEAD PHARMACEUTICALS INC","titleOfClass":"Common","cusip":"04280A100","value":925591288,"shares":11355555,"shareType":"SH","priorValue":670889937,"priorShares":10699999},{"issuer":"KYMERA THERAPEUTICS INC","titleOfClass":"Common","cusip":"501575104","value":857129238,"shares":7474747,"shareType":"SH","priorValue":622571678,"priorShares":7474747},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"Common","cusip":"76155X100","value":430182160,"shares":2297000,"shareType":"SH","priorValue":227997179,"priorShares":2344444},{"issuer":"CYTOKINETICS INC","titleOfClass":"Common","cusip":"23282W605","value":425949915,"shares":4999999,"shareType":"SH","priorValue":219699978,"priorShares":3333333},{"issuer":"CELCUITY INC","titleOfClass":"Common","cusip":"15102K100","value":355708000,"shares":3400000,"shareType":"SH","priorValue":385222500,"priorShares":3375000}],"positionsListed":26,"positions":[{"issuer":"UNITED THERAPEUTICS CORP","titleOfClass":"Common","cusip":"91307C102","value":1505082912,"shares":2777777,"shareType":"SH","priorValue":1559537400,"priorShares":2630000},{"issuer":"ASCENDIS PHARMA","titleOfClass":"ORDINARY SHARES","cusip":"K08588103","value":1363235526,"shares":5111111,"shareType":"SH"},{"issuer":"KRYSTAL BIOTECH INC","titleOfClass":"Common","cusip":"501147102","value":1073713003,"shares":2888888,"shareType":"SH","priorValue":746257548,"priorShares":2888888},{"issuer":"MADRIGAL PHARMACEUTICALS INC","titleOfClass":"Common","cusip":"558868105","value":984408154,"shares":1833333,"shareType":"SH","priorValue":951763208,"priorShares":1818181},{"issuer":"ARGENX SE","titleOfClass":"Sponsored ADR","cusip":"04016X101","value":927770000,"shares":1000000,"shareType":"SH","priorValue":730250000,"priorShares":1000000},{"issuer":"ARROWHEAD PHARMACEUTICALS INC","titleOfClass":"Common","cusip":"04280A100","value":925591288,"shares":11355555,"shareType":"SH","priorValue":670889937,"priorShares":10699999},{"issuer":"KYMERA THERAPEUTICS INC","titleOfClass":"Common","cusip":"501575104","value":857129238,"shares":7474747,"shareType":"SH","priorValue":622571678,"priorShares":7474747},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"Common","cusip":"76155X100","value":430182160,"shares":2297000,"shareType":"SH","priorValue":227997179,"priorShares":2344444},{"issuer":"CYTOKINETICS INC","titleOfClass":"Common","cusip":"23282W605","value":425949915,"shares":4999999,"shareType":"SH","priorValue":219699978,"priorShares":3333333},{"issuer":"CELCUITY INC","titleOfClass":"Common","cusip":"15102K100","value":355708000,"shares":3400000,"shareType":"SH","priorValue":385222500,"priorShares":3375000},{"issuer":"STRUCTURE THERAPEUTICS INC","titleOfClass":"SPONSORED ADS","cusip":"86366E106","value":351836637,"shares":6555555,"shareType":"SH","priorValue":315977751,"priorShares":6555555},{"issuer":"XENON PHARMACEUTICALS INC","titleOfClass":"Common","cusip":"98420N105","value":348746620,"shares":5777777,"shareType":"SH","priorValue":335977733,"priorShares":5777777},{"issuer":"DEFINIUM THERAPEUTICS INC","titleOfClass":"Common","cusip":"24477V105","value":338165292,"shares":7188888,"shareType":"SH","priorValue":94500000,"priorShares":5000000},{"issuer":"UNIQURE NV","titleOfClass":"Common","cusip":"N90064101","value":309881409,"shares":6727777,"shareType":"SH","priorValue":97439378,"priorShares":5959595},{"issuer":"VERA THERAPEUTICS INC","titleOfClass":"Common","cusip":"92337R101","value":245612034,"shares":5723888,"shareType":"SH","priorValue":236909964,"priorShares":5888888},{"issuer":"TAYSHA GENE THERAPIES INC","titleOfClass":"Common","cusip":"877619106","value":162683327,"shares":23888888,"shareType":"SH","priorValue":96999000,"priorShares":21700000},{"issuer":"OCULAR THERAPEUTIX INC","titleOfClass":"Common","cusip":"67576A100","value":123142800,"shares":12540000,"shareType":"SH","priorValue":104308050,"priorShares":12315000},{"issuer":"DAMORA THERAPEUTICS INC","titleOfClass":"Common","cusip":"36322Q206","value":98395830,"shares":3783000,"shareType":"SH","priorValue":97979700,"priorShares":3783000},{"issuer":"HEMAB THERAPEUTICS HLDGS INC","titleOfClass":"Common","cusip":"423494103","value":70710760,"shares":1925150,"shareType":"SH"},{"issuer":"GH RESEARCH PLC","titleOfClass":"ORDINARY SHARES","cusip":"G3855L106","value":48384000,"shares":1800000,"shareType":"SH","priorValue":25308000,"priorShares":1800000},{"issuer":"VIRIDIAN THERAPEUTICS INC","titleOfClass":"Common","cusip":"92790C104","value":45925000,"shares":2500000,"shareType":"SH","priorValue":29340000,"priorShares":1500000},{"issuer":"SEPTERNA INC","titleOfClass":"Common","cusip":"81734D104","value":44792875,"shares":1337500,"shareType":"SH","priorValue":32140125,"priorShares":1337500},{"issuer":"AVALO THERAPEUTICS","titleOfClass":"Common","cusip":"05338F306","value":43119994,"shares":2333333,"shareType":"SH","priorValue":21051300,"priorShares":1410000},{"issuer":"FAETH THERAPEUTICS INC","titleOfClass":"COMMON","cusip":"81728A207","value":36100975,"shares":1444039,"shareType":"SH"},{"issuer":"WHITEHAWK THERAPEUTICS INC","titleOfClass":"Common","cusip":"00032Q104","value":13050261,"shares":2849402,"shareType":"SH","priorValue":9830437,"priorShares":2849402},{"issuer":"LEXEO THERAPEUTICS INC","titleOfClass":"Common","cusip":"52886X107","value":6932175,"shares":1489189,"shareType":"SH","priorValue":10762500,"priorShares":1875000}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva Wealth is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}